IMM Immupharma Plc

TIDMIMM

RNS Number : 7432G

Immupharma PLC

05 March 2018

 
 5 March 2018 
 
 

ImmuPharma PLC

("ImmuPharma" or the "Company")

AIM Rule 17 Notice

ImmuPharma PLC (LSE: IMM), specialist drug discovery and development company, announces pursuant to Rule 17 of the AIM Rules for Companies ("AIM Rules"), the following director's disclosure under Schedule Two, Paragraph (g) of the AIM Rules:

Tim McCarthy, the Company's Non-executive Chairman, is currently on the board of Harvard Healthcare Limited ("Harvard"). On 5 March 2018 the Directors of Harvard passed a board resolution following which Harvard will be placed into a Creditors' Voluntary Liquidation.

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014.

-Ends-

 
 For further information please 
  contact: 
                                           + 44 (0) 20 
   ImmuPharma plc (www.immupharma.org)       7152 4080 
   Tim McCarthy, Chairman 
   Lisa Baderoon, Head of Investor 
    Relations 
    lisa.baderoon@immupharma.com          + 44 (0) 7721 
    Twitter: @immupharma                      413496 
   Northland Capital Partners Limited 
    (NOMAD & Broker) 
    David Hignell, Dugald J. Carlean, 
    Jamie Spotswood, Corporate Finance    +44 (0)20 3861 
    Rob Rees, Corporate Broking                6625 
 

This information is provided by RNS

The company news service from the London Stock Exchange

END

AMOEAKDSEFFPEFF

(END) Dow Jones Newswires

March 05, 2018 11:13 ET (16:13 GMT)

Immupharma (LSE:IMM)
Historical Stock Chart
From Mar 2024 to Apr 2024

Immupharma (LSE:IMM)
Historical Stock Chart
From Apr 2023 to Apr 2024